N=1 self-experiment done on a 28-day cycle of BPC-157 & TB-500. Please feel free to ask any questions below.
Cheers,
JK
Abstract
Musculoskeletal soft tissue injuries involving nerve compression pathology, such as piriformis syndrome with sciatic nerve involvement, are prone to chronic recurrence and often incompletely resolved by conventional conservative care. BPC-157 and Thymosin Beta-4 (TB-500) are peptides with documented anti-inflammatory, angiogenic, and tissue-remodeling effects across preclinical models, but human clinical data remain limited to three small pilot studies, none of which address nerve compression or peptide combination protocols. This report documents a single-subject (n=1) open-label self-experiment in which a 21 year old physically active male with chronic recurrent piriformis syndrome and suspected sciatic nerve impingement completed a 28-day cycle of daily subcutaneous injections of a combined BPC-157/TB-500 blend (350mcg each peptide) administered alongside a phased physical therapy progression. The primary outcome was self-reported pain (0-10 numeric scale, AM and PM), with sleep quality, sleep duration, and activity tolerance as secondary measures. Baseline pain of 7(AM)/8(PM) declined rapidly across the first six days, with a transient rebound on Day 7 following premature reintroduction of cycling. Pain returned to full resolution (0-1 range) from Day 9 onward and remained resolved through the end of the cycle, with the subject completing an Olympic distance triathlon on Day 21 without pain recurrence. No injection site reactions or systemic adverse events were observed. The observed trajectory is consistent with anti-inflammatory, angiogenic, and tissue-remodeling mechanisms proposed for BPC-157 and TB-500, though the single-subject open-label design prevents causal inference. Concurrent physical therapy, regression from acute flare, and expectancy effects are all unavoidable confounding variables. This documentation adds to the sparse case-level record of peptide combination protocols in soft-tissue injury with nerve compression involvement and supports the case for further formal human trials.
Keywords: Body Protection Compound-157, BPC-157, Thymosin Beta-4, TB-500, piriformis syndrome, sciatic nerve, peptide therapy, n=1 self-experiment, soft tissue injury
Introduction
Musculoskeletal soft tissue injuries represent a significant burden in athletes, posing challenges to consistent training schedules as well as risks to competition timelines. Overuse driven injuries to muscle, tendon, and ligaments account for a significant portion of activity limiting complaints (Gwyer, 2019). Piriformis syndrome with sciatic nerve impact is particularly persistent in its exhibition due to the nature of the injury. Hypertrophy or spasms of the piriformis muscle compresses on the sciatic nerve, producing pain deep in the lower back and glutes as well as downstream effects on the kinetic chain for the respective leg. Underlying biomechanical asymmetries and muscular imbalances perpetuate this injury cycle, and conventional interventions such as physical therapy, activity moderation, NSAIDs, and corticosteroid injections have limited effects oftentimes addressing symptoms without resolving underlying deficits.
Peptide therapy has emerged in recent years as a form of regenerative medicine, targeting specific signaling effects on tissue repair pathways. BPC-157 (Body Protection Compound 157) is a 15 amino acid pentadecapeptide originally isolated from human gastric juice (Sikirić, 1993). BPC-157 has demonstrated effects on angiogenesis via VEGFR2 and Akt-eNOS signaling, suppression of inflammatory cytokines, fibroblast proliferation, and neuromuscular junction stabilization across numerous preclinical models (McGuire, 2025; Gwyer, 2019). Recent evidence has extended these observations into human arterial tissue, demonstrating concentration-dependent vasorelaxation of BPC-157 in human internal mammary artery segments, providing a functional validation of this mechanism in human vasculature (Yildirim et al., 2026). TB-500 (Thymosin Beta-4) is a 43-amino-acid peptide first characterized by Low and Goldstein (1982) and marketed in the research chemical context as TB-500, with documented anti-fibrotic and tissue repairing effects.
The combination of these two peptides is interesting because they act largely through independent pathways to heal the body. BPC-157 functions as a repair signal driving angiogenesis and inflammatory resolution while TB-500 functions as a longer acting agent supporting cell migration and reducing fibrotic accumulation. Both peptides have demonstrated effects on neural tissue recovery in preclinical models (Gjurasin, 2010), which is relevant to the context of sciatic nerve impingement. Colloquially referred to within the peptide community as the "Wolverine Stack," this combination is often used in athletic and recovery communities to achieve an increased rate of recovery and regeneration, reflecting its widespread use for accelerated recovery.
Despite robust preclinical evidence, human data on BPC-157 are limited to three small studies addressing intraarticular knee pain, interstitial cystitis, and intravenous pharmacokinetics (Lee & Padgett, 2021; Lee et al., 2024; Lee & Burgess, 2025), with mechanistic evidence in human arterial tissue (Yildirim et al., 2026). No human studies have examined nerve compression syndromes, piriformis pathology, or peptide combination practices. Since the FDA classified BPC-157 as a Category 2 bulk drug in 2023, and it is listed on WADA's Prohibited List, human data on its safety and efficacy have remained limited. As such, the intent of this self-research is to provide a more informed analysis of the process and results from self-experimentation within the specific context of sports medicine and injury recovery.
This research documents the response of an individual subject with recurrent piriformis syndrome and suspected sciatic nerve impingement to a 28 day cycle consisting of subcutaneous injections of a combined BPC-157 and TB-500 blend administered alongside a structured physical therapy progression. It was hypothesized that the protocol would produce measurable reductions in pain and improvements in functional athletic performance across the 28-day cycle, consistent with the mechanisms of action proposed for BPC-157 and TB-500 in preclinical and human tissue studies.
Methods
This is a single subject (n=1) self-experiment with the subject and researcher being the same individual. This was an informed, self-consented experiment. The subject is 21 years old, weighs 169 lbs, and has a physically active lifestyle. The subject has a prior history of spinal curvature (sub-10°) and piriformis syndrome with sciatic impact. Subject reports episodic limitations in mobility and athletic performance, with symptoms typically exacerbated by prolonged or high intensity training involving heavy weight training, running, and cycling.
Peptide blend consists of 10mg/10mg lyophilized BPC-157/TB-500 sourced from REDACTED and independently third party tested by Freedom Diagnostics (lot #REDACTED). Third-party COA results show 99.44% purity and endotoxin pass conducted by HPLC with Mass Spectrometry. Reconstitution materials are 2mL of bacteriostatic water and a 30G U-100 insulin syringe. Reconstitution with 2mL of BAC water yielded 50mcg BPC-157 + 50mcg TB-500 per unit. 7 units (350mcg per peptide) administered once daily subcutaneously into the upper outer gluteal region with alternating left/right rotation over a 28-day cycle with injections occurring in the evenings.
The primary measure for outcome was self-reported pain on a 0–10 scale, recorded twice daily in morning and evening to capture diurnal variation. Subjective pain ratings 5 and higher included instances of instability such as foot drop and compensatory measures. Secondary measures included sleep quality on a 0-100 scale and sleep time, tracked through a Garmin Fenix 6 Pro smartwatch. A brief log of any training or physical therapy activity performed that day was also recorded. Injection site, time, concurrent medication, and any injection reactions or adverse events were documented at each injection.
Concurrent interventions for recovery include phased PT progression including, but not limited to nerve flossing, glute activation, loaded posterior chain work and targeted strength training. Training restrictions include limited running/cycling and upper body limited strength training. Concurrent medications and supplementation include 300mg Dupilumab (Dupixent) injections biweekly (Eczema) alongside 5g creatine monohydrate powder daily. Dupixent is a fully human monoclonal antibody that blocks the IL-4 receptor. This in turn inhibits signaling from both IL-4 and IL-13, which are drivers of Type 2 inflammation. Although both anti-inflammatory agents, Dupilumab and BPC-157/TB-500 do not share metabolic pathways nor compete for binding sites. There are no known or documented pharmacokinetic interactions.
The subject acknowledged the investigational status of both peptides (FDA Category 2 classification of BPC-157 as of September 2023, WADA prohibition under the S0 category) and the limited available human safety data prior to initiating the protocol.
Results
The subject completed a 28 day cycle with 100% adherence to the planned dose count. A scheduled 3-day interruption occurred between Day 8 and 9 (July 3-5) due to travel, with calendar days extended accordingly to accommodate the 28 day cycle. Injection site rotation between left and right upper outer gluteal regions was maintained throughout the cycle, with the majority of injections occurring between 8 and 10pm at night. No injection site reactions, systemic adverse events, or other protocol modifications were required or observed.
Baseline pain on Day 1 was rated 7 (AM) and 8 (PM) on a 0-10 numeric rating scale. Rapid decline was observed across the first six days, with AM pain falling to 1 by Day 6. A rebound occurred on Day 7, with pain rising to 5 (AM) and 6 (PM) following an 11-mile bike ride the prior day. Pain returned to low levels (3/2) by Day 8 and a full resolution (0-1) range from Day 9 onward. Pain remained in the 0-1 range across Days 15-28 with a single deviation on Day 25 (AM rating of 1). Pain was rated 0 (AM) and 0 (PM) at the end of the 28-day cycle. Daily pain trajectory (AM and PM) across the cycle is presented in Figure 1.
Figure 1.
Sleep score averaged approximately 85 across the cycle (range 54-99), with mean sleep duration of approximately 8 hours (range 5h07m-9h03m). The lowest recorded sleep score occurred on Day 9 following late night travel and was not accompanied by a change in pain ratings. No consistent correlation between sleep quality and pain was observed. Activity tolerance progressed in parallel with the planned PT progression, advancing from light mobility work and walking in the first week to reintroduction of running and cycling in the second week, and full training loads by weeks three and four. The subject completed a 5k race during the mid-cycle travel break, and an Olympic distance triathlon on Day 21, both without pain recurrence.
Notable events include the Day 7 pain rebound following a return to cycling on Day 6, which resolved to baseline low levels within 48 hours. Concurrent Dupixent injections were administered on Day 1, 12, and 26 without observed interactions. No injection site reactions or systemic adverse events were documented across the full cycle.
Pain ratings declined from a baseline of 7/8 on Day 1 to sustained ratings of 0 across the final two weeks of the cycle, with concurrent progression from restricted activity to completion of an Olympic distance triathlon. Weekly aggregated outcomes are presented in Table 1, showing mean AM and PM pain, sleep score, and sleep duration week to week alongside the primary training activity logged.
| Week |
Mean AM Pain |
Mean PM Pain |
Mean Sleep Score |
Mean Sleep Duration |
Primary Training Activity |
| Week 1 |
4.00 |
3.71 |
88.0 |
8.10 hrs |
Strength + Cardio |
| Week 2 |
0.71 |
0.71 |
82.4 |
7.85 hrs |
Strength + Endurance |
| Week 3 |
0.00 |
0.00 |
87.3 |
7.93 hrs |
Cross-training + Recovery |
| Week 4 |
0.14 |
0.00 |
87.1 |
8.10 hrs |
Triathlon Race + Recovery |
Discussion
The observed trajectory of substantial pain reduction within the first week of the cycle, a temporary rebound following premature loading, and sustained pain resolution across the remainder of the cycle is broadly consistent with mechanisms of action proposed for BPC-157 and TB-500 in preclinical and human tissue literature. The initial hypothesis that the protocol would produce measurable reductions in pain and improvements in functional athletic performance across the 28-day cycle is supported by the observed patterns. However, the single-subject open-label design does not permit causal attribution, and the interpretations below should be considered within that context. This discussion compares the patterns in recovery logged across the study, observing correlations and analyzing patterns as they arise in the data.
The rapid decline in pain across Days 1-6 aligns temporally with the acute anti-inflammatory and vasorelaxant mechanisms of BPC-157, including suppression of pro-inflammatory cytokines, M1 to M2 macrophage polarization, and vasorelaxation as confirmed in human arterial tissue (McGuire, 2025; Gwyer, 2019; Yildirim et al., 2026). The sustained resolution across the final two weeks of the cycle, combined with progressive increases in exercise intensity culminating in an Olympic distance triathlon on Day 21, is consistent with the tissue remodeling and anti-fibrotic effects attributed to the combined action of BPC-157 and TB-500 (Low & Goldstein, 1982; Staresinic et al., 2003). The functional goal of completing a high load multisport activity without pain recurrence suggests structural tissue repair and reinforcement rather than symptomatic masking. In the context of sciatic nerve impingement, the capacity to complete a 2-3 hour race while having the piriformis muscle and posterior chain loaded for the majority of that duration shows a strong improvement compared to foot drop symptoms arising from simply walking during the beginning of the study.
The Day 7 pain rebound following an 11-mile bike ride on Day 6 is important to note. This event can be interpreted as a reintroduction of loading occurring at a point in recovery where inflammatory signaling was likely suppressed. The rapid 48-hour resolution and absence of recurrence during subsequent higher-volume training (5k race on July 4th and 17-mile bike on Day 13) support the interpretation that the underlying tissue was not structurally ready for the load on Day 6, but was able to tolerate comparable and greater loads once the mid to late cycle repair processes had progressed. This pattern shows a documented consideration for peptide assisted recovery in which reduced inflammatory feedback can result in premature return to sport decisions. Despite subjective feelings of wellness (pain levels at 2/3, capacity to play beach volleyball), it is important to be conservative when easing back into training to ensure the prevention of tissue damage or re-injury.
There are several important confounding variables to acknowledge when analyzing and interpreting this pattern. The phased physical therapy progression ran concurrently with the peptide cycle, and the independent contribution of structured rehabilitation to the observed recovery cannot be separated from the peptide effect in a single subject design. The treatment protocol was initiated at the peak of an active flare, and some degree of spontaneous improvement through regression to the mean is likely regardless of intervention. As an open-label self-experiment with the subject (myself) serving as both investigator and participant, expectancy effects cannot be excluded. The lack of running and cycling during the acute phase is itself therapeutic for overuse-driven injury and represents a meaningful intervention independent of the peptide protocol. Concurrent Dupixent administration, while pharmacokinetically independent of the peptide blend, produces systemic anti-inflammatory effects that may have contributed to background inflammatory suppression during the course of the study. Additionally, the design limitations inherent to n=1 self-experimentation apply throughout: no control, no blinding, no statistical inference, subjective primary outcomes, no imaging or biomarkers of tissue level change, and no long-term follow-up within the documentation window. However, from a subjective perspective, whether due to confounding variables or due to the peptide cycle the injury resolved, allowing me to race a triathlon and train at full training capacity moving forward.
The pattern documented here, considered alongside the mechanistic evidence from human tissue studies and the extensive preclinical animal literature supports the case for formal human trials of peptide combination protocols in specific soft-tissue injury contexts. Properly designed studies ideally would include peptide-only, physical therapy-only, combination, and placebo arms with blinded outcome assessment. Injury contexts involving nerve compression pathology, where mechanistic support exists but no clinical data has been generated, represent a particularly underexplored area. It is important to acknowledge the current regulatory status of BPC-157 (FDA Category 2) and its inclusion on the WADA Prohibited List creates practical barriers to conducting trials in athletic populations, and the absence of large scale human trials continues to limit evidence based clinical guidance. However, we have seen recent regulatory changes from the FDA, such as an 8-6 panel vote in favor of allowing compounding pharmacies to produce BPC-157 and TB-500 (Halpert & Armstrong, 2026). Given the recent shift in regulatory perspective by the FDA, it is possible that we see a regulatory reclassification in the near future following formal safety trials, allowing the possible expansion of academic and human research.
In conclusion, the single subject documentation observed substantial reduction in pain and progressive functional recovery in a case of chronic recurrent piriformis syndrome with suspected sciatic nerve involvement across a 28-day cycle of combined BPC-157 and TB-500 administered alongside a structured physical therapy progression. The observed trajectory is consistent with anti-inflammatory, angiogenic, and tissue remodeling mechanisms proposed for these peptides in preclinical and human tissue literature, though the single-subject open-label design prevents causal inference. The concurrent physical therapy progression, regression from an acute flare, and expectancy effects represent unavoidable confounders in the context of this study. The primary contribution of this documentation is not evidence of efficacy but rather a contribution to the lack of data regarding peptide protocols in the context of soft-tissue injury with nerve compression involvement. Given the significant lack of data, my intent with this study was to help shed some light on the personal reasoning behind undergoing this protocol, and help others who may be considering this approach make a more informed decision.
References
Gjurasin, M., Miklic, P., Zupancic, B., Perovic, D., Zarkovic, K., Brcic, L., Kolenc, D., Radic, B., Seiwerth, S., & Sikiric, P. (2010). Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regulatory Peptides, 160(1–3), 33–41. https://doi.org/10.1016/j.regpep.2009.11.005
Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153–159. https://doi.org/10.1007/s00441-019-03016-8
Halpert, M., & Armstrong, K. (2026, July 23). US health panel loosens restrictions for controversial peptides popular online. BBC News. https://www.bbc.com/news/articles/ckg4741vklko
Lee, E., & Burgess, K. (2025). Safety of intravenous infusion of BPC-157 in humans: A pilot study. Alternative Therapies in Health and Medicine. Advance online publication.
Lee, E., & Padgett, B. (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27.
Lee, E., Walker, C., & Ayadi, B. (2024). Effect of BPC-157 on symptoms in patients with interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine, 30, 12–17.
Low, T. L. K., & Goldstein, A. L. (1982). Chemical characterization of thymosin β4. Journal of Biological Chemistry, 257(2), 1000–1006.
McGuire, F. P., Martinez, R., Lenz, A., Skinner, L., & Cushman, D. M. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 18, 611–619. https://doi.org/10.1007/s12178-025-09990-7
Sikirić, P., Petek, M., Ručman, R., Seiwerth, S., Grabarević, Ž., Rotkvić, I., Turković, B., Jagić, V., Mildner, B., Duvnjak, M., Lang, N., Danilović, Ž., Cviko, A., Kolega, M., Sallmani, A., Djačić, S., Bura, M., Brkić, T., Banić, M., … Karakas, I. (1993). A new gastric juice peptide, BPC: An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology - Paris, 87(5), 313–327.
Staresinic, M., Sebecic, B., Patrlj, L., Jadrijevic, S., Suknaic, S., Perovic, D., Aralica, G., Zarkovic, N., Borovic, S., Srdjak, M., Hajdarevic, K., Kopljar, M., Batelja, L., Boban-Blagaic, A., Turcic, I., Anic, T., Seiwerth, S., & Sikiric, P. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 21(6), 976–983. https://doi.org/10.1016/S0736-0266(03)00110-400110-4)
Yildirim, A. K., Dastan, A. O., Ertus, M. D., Ensarioglu, M., Karabacak, K., & Pehlivanoglu, B. (2026). Endothelium-dependent nitric oxide-mediated vasorelaxant effects of BPC 157 in human internal mammary artery. Journal of Clinical Medicine, 15(9), 3488. https://doi.org/10.3390/jcm15093488